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Three-dimensional (3d) real-time conformal brachytherapy – a novel
solution for prostate cancer treatment
Part II. A feasibility clinical pilot study
Marek Fija∏kowski1, Brygida Bia∏as1, Bogus∏aw Maciejewski2,
Joanna Bystrzycka3, Krzysztof Âlosarek3
O b j e c t i v e s.  The pilot feasibility clinical study was designed to test the tolerance and early efficacy of the 3D-real time
conformal brachytherapy combined with external irradiation of patients with prostate cancer.
M a t e r i a l  a n d  m e t h o d s.  Seventy six consecutive patients with prostate cancer in stage T1-2N0M0 entered the study.
Median pretreatment PSA level was 13.6 ng/ml and Gleason score was 8 or lower. All patients received conformal external
irradiation of 54 Gy in 27 fractions followed by a 10 Gy boost given using 3D-real time CBRT.
Re s u l t s.  All patients tolerated the CBRT implant procedure and prior external irradiation very well, with no discomfort, and
no protocol violation was noted. Acute urinary bladder toxicity grade III was noted in 1% of patients. There were no grade III
gastrointestinal acute toxicity. Mild, grade I or II toxicity, was observed in 62% of patients and it did not significantly
influence patient comfort. Early actuarial 1-year BNED was 97.3%. Dosimetric analysis has shown that the mean value of
D100PTV was 91.7%, D90 was 97.6% and D10 for the urethra was 126.3%. All dosimetric parameters were within the limits
recommended by the American Brachytherapy Society (ABS).
C o n c l u s i o n s.  3D-real time conformal brachytherapy using a single boost dose of 10 Gy combined with 54 Gy in 27
fractions of conformal irradiation is a safe and well tolerated treatment in case of patients with T1-2N0M0 prostate cancer.
From the radiobiological point of view there is still room to intensify treatment towards fractionated 3D-real time CBRT
interdigited with external irradiation.
Trójwymiarowa brachyterapia w „czasie rzeczywistym”
– nowa metoda leczenia chorych na raka gruczo∏u krokowego
Cz´Êç II. Pilotowe badanie kliniczne
Z a ∏ o ˝ e n i a.  Zaplanowano i przeprowadzono pilotowe badanie kliniczne w grupie chorych na raka gruczo∏u krokowego
w celu oceny tolerancji i skutecznoÊci konformalnej brachyterapii 3D – w czasie rzeczywistym, skojarzonej z konformalnà
radioterapià przy u˝yciu zewn´trznych wiàzek promieniowania.
M a t e r i a ∏  i m e t o d y k a.  Grup´ pilotowà stanowi∏o 76 kolejnych chorych na raka gruczo∏u krokowego w stopniu
zaawansowania T1-2N0M0. Ârednia wartoÊç st´˝enia PSA przed rozpocz´ciem leczenia wynosi∏a 13,6 ng/ml, a stopieƒ
Gleasona nie przekracza∏ 8. Wszyscy chorzy byli napromieniani dawkà 54 Gy w 27 frakcjach, po której podawano dawk´
uzupe∏niajàcà 10 Gy przy u˝yciu 3D-CBRT w czasie rzeczywistym.
W y n i k i.  U wszystkich chorych tolerancja by∏a bardzo dobra. Ostry odczyn popromienny w III stopniu ze strony uk∏adu
moczowego wystàpi∏ u 1% pacjentów. U ˝adnego chorego nie stwierdzono III stopnia nasilenia ostrego odczynu w odbytnicy.
S∏abe i miernie nasilone odczyny I i II stopnia wystàpi∏y u 62% chorych i nie wp∏ywa∏y istotnie na komfort leczenia. Wczesne,
zaktualizowane 1-roczne prze˝ycie bez wznowy biochemicznej wynios∏o 97,3%. Wyniki analizy dozymetrycznej wykaza∏y
Êrednie wartoÊci parametrów D100PTV 91,7%, D90=97.6%, D10=126,3% i mieÊci∏y si´ w przedzia∏ach odpowiednich
wartoÊci, rekomendowanych przez Amerykaƒskie Towarzystwo Brachyterapii.
W n i o s k i.  Konformalna brachyterapia 3D w czasie rzeczywistym, zastosowana w formie dawki 10 Gy, uzupe∏niajàcej
konformalne napromienianie dawkà 54 Gy w 27 frakcjach, jest bezpiecznà i dobrze tolerowanà metodà skojarzonego
leczenia chorych na raka gruczo∏u krokowego w stopniu zaawansowania T1-2N0M0. Przes∏anki radiobiologiczne wskazujà
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Introduction
Patients with early stage of prostate cancer (T1-T2)
without nodal involvement (N0) and distant metastases
(M0) and with the PSA level of less of or equal to 10
ng/ml and Gleason scores of ≤7 are considered as a low
risk subgroup of patients and have variety of treatment
options, e.g. radical prostatectomy, conformal external
beam radiotherapy, or brachytherapy. Brachytherapy is
usually applied as a boost dose treatment. This subgroup
has been chosen for the pilot “feasibility” study to
evaluate the practical applicability of 3D- conformal
“real time” brachytherapy (3D-CBRT) and its tolerance.
The method is presented in details in part I of this
paper [1].
Material and methods
E l i g i b i l i t y  c r i t e r i a
We chose the following eligibility criteria for the 3D- real time
CBRT: (1) clinical T1-T2 without pelvic nodal disease and other
distant metastases (N0M0); (2) biopsy-confirmed adeno-
carcinoma with pretreatment PSA level and Gleason score; (3)
no contraindication for spinal anesthesia; (4) signed informed
consent. All patients have been previously seen and qualified by
the Prostate Cancer Team at the Institute.
M a t e r i a l
Between January 1, 2003 and June 30, 2004, 76 patients with
prostate cancer in stage T1-T2N0M0 have been qualified for
the 3D- real time CBRT given as a boost dose at the beginning
or at the end of conformal external irradiation. The median age
of patients was 65 years (range 57-81). A majority of patients
were between 50 and 70 years old. Of the 76 patients two had
Gleason score 8, nine had Gleason score 7, and the remaining 65
patients (86%) had Gleason score below 7.
PSA level prior to the treatment was equal to, or lower
than 10 ng/ml in 30 cases (40%). There were 5 patients with
PSA level above 50 ng/ml (Table I,A). Median pretreatment
PSA was 13.6 ng/ml (Figure 1A). There were 11 patients (14%)
with two poor prognostic factors (PSA>10 ng/ml, GS>7). Sixty
six of the 76 patients (87%) received hormonotherapy (mainly
Zoladex or Flutomid, or both) prior to radiation therapy. None
of the patients underwent surgery.
R a d i o t h e r a p y
All patients received conformal external irradiation (3D-CERT)
of 44 Gy in 22 fractions given once-a-day to a large pelvic PTV
and followed by a 10 Gy boost in 5 fractions targeted to the
prostate using 3D-conformal technique.
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na mo˝liwoÊç intensyfikacji leczenia w kierunku frakcjonowanej brachyterapii 3D w czasie rzeczywistym, kojarzonej
naprzemiennie z konformalnà radioterapià, przy u˝yciu zewn´trznych wiàzek promieniowania.
Key-words: 3D conformal-real time brachytherapy, pilot clinical study, acute effects and tolerance
S∏owa kluczowe: konformalna brachyterapia 3D w czasie rzeczywistym, pilotowe badanie kliniczne, ostre odczyny
popromienne i tolerancja
Table I. PSA level (A) before and (B) after ERT-BRT
(A)
PSA LEVEL No pts (%)
ng/ml
<6.0 12 15.5%
6.01-10.0 18 24.0%
10.01-20.0 27 36.0%
20.01-50.0 14 18.0%
>50.0 5 6.5%
(B)
PSA LEVEL No pts (%)
ng/ml
≤0.5 54 71%
0.51-1.0 10 13%
1.01-1.5 3 4%
1.51-2.0 2 3%
>2.0* 7 9%
* for one patient PSA increased from 68.4 ng/ml to 82 ng/ml
Figure 1. Cumulative rate of the PSA levels (A) before and (B) after
3D-CERT + 3D-CBRT
B r a c h y t h e r a p y
Basing on the TRUS images the prostate volume (pV) was
estimated (Table II). In 66 patients (87%) the pV was within
the range of 18-40 cc. A single dose of
Table II. Prostate volume at the time of 3D-CBRT
Prostate No. pts %
volume
<20 cc 18 24%
20.5-30 cc 33 43%
30.5-40 cc 15 20%
40.5-50 cc 8 10%
50.5-55 cc 2 3%
10 Gy was delivered one or two days after completing
CERT, using the technique described in part I of this paper.
The implant consisted of 12-18 needles (in the majority of cases
– 17 or 18 needles had been inserted). The prescribed dose was
measured on the surface (contour) of the prostate capsule.
D o s i m e t r i c  a n a l y s i s
According to the American Brachytherapy Society Recommen-
dations (ABS), values of D100PTV (percentage of the PTV
volume covered by 100% isodose) and D90 (dose delivered to
90% of the target volume) were measured and recorded to
evaluate the quality of the treatment. To evaluate the level and
range of doses delivered to the urethra the D10 (dose delivered
to 10% volume of the urethra) was measured. The rectal dose
was estimated in the rectal reference point, as described by
Martinez et al [2].
Results
Tr e a t m e n t  c o m p l i a n c e
After signing informed consent all patients underwent
3D-CERT and 3D-CBRT implants as initially prescribed.
No patient was excluded from the analysis.
P SA  o u t c o m e
Figure 1B shows the cumulative pattern of PSA after
treatment compared with the pretreatment PSA levels.
Prior to treatment 60% of patients had PSA at a level
≥10 ng/ml, and after therapy in 84% of patients PSA
decreased to a level of less than 1 ng/ml (Table 1B). The
mean post-treatment PSA value was 0.13 ng/ml. This
gives, on average, a 100-fold magnitude of the decrease in
the PSA level as compared with the mean pretreatment
value. Nevertheless, in 34 cases (45%) even 200-1000 fold
differences between pre-and post-treatment PSA levels
have been noted, especially in those cases where the
pretreatment PSA was high (>15ng/ml). Only in two
patients did the PSA level increase after treatment, as
compared with the pretreatment values.
Analyzing the impact of prognostic factors on the
PSA level (Table III), among the 48 patients with one or
two poor prognostic factors (PSA ≥10 ng/ml, GS ≥7),
PSA after treatment of more than 1 ng/ml has been noted
in 17% of patients with one poor prognostic factor, and in
27% of patients with two poor prognostic factors, as
compared to only 9% of patients in the “favourable”
group. Among 76 patients one patient developed distant
bone and lung metastases 3 months after completing the
treatment (GS=7, PSA=54.3 ng/ml).
Table III. Biochemical remission depending on the number
of poor prognostic factors prior to treatment
Patient category: No pts. with higher PSA 
(poor prognostic factors) level than 1ng/ml after ERT-BRT
none 3/28 – 9%
one: Gleason ≥7 0/2 – 0%
PSA > 10 ng/ml 6/35 – 17%
two: both Gl and PSA 3/11 – 27%
Because follow-up is still relatively short, within the
range of 3-18 months, it does not allow to estimate long
term results, but early results show 97.3% of 1-year
BNED (biochemical no evidence of disease).
A c u t e  t o x i c i t y
All patients tolerated the implant procedure very well,
without discomfort. Generally, the entire treatment
course of combined conformal ERT and BRT was well
tolerated and we observed no acute effects requiring
treatment modification. The treatment-related acute
toxicities were primarily gastrointestinal and urinary.
Acute grade III urinary toxicity was observed in 1% of
patients. No severe acute effects (grade IV) have been
noted (Table IV). Mild perineal pain occurred in 11% of
patients, but it was transient. In the group of patients
with a minimum follow-up of 12 months, no chronic
gastrointestinal and urinary toxicities have been observed.
All other mild toxicities were of grade I or II (62%) and
could be expected to occur in patients with pelvic external
irradiation. For the combined treatment tested it is
difficult to separate the toxicities related to the 3D-CBRT
from those caused by external irradiation, however it was
observed that an extra boost of10 Gy of 3D-CBRT did not
significantly increase the severity of the already observed
CERT-related acute effects.
Table IV. Acute toxicity scored using EORTC system during
and directly after completing 3D-ERT + 3D-CBRT for prostate cancer
CRITICAL Acute toxicity grade EORTC
ORGAN 0° I° II° III° IV°
bladder 50.5% 42% 6.5% 1% 0%
rectum 76% 20% 4% 0% 0%
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D o s i m e t r i c  r e s u l t s
The parameter D100PTV (percentage of PTV volume
covered by 100% isodose) was 91.7% (80.3-95.8%). The
row measurements scattergram show that for 72% of
cases D100PTV was ≥90% (Figure 2a). The mean D90
(dose delivered to at least 90% of the target volume) was
97.6% (86.4-109.1%). The D90 scattergram (Figure 2b)
shows that for 82% of cases D90 was ≥95%. The urethral
D10 (dose delivered to 10% volume of the urethra) for
95% of cases was in the range of 120% and 130% (Figure
2c) and the mean value was 126.3% (120.5-170.1%). The
rectal doses were not higher than 65% of the prescribed
dose.
Discussion
For years, locally advanced prostate cancer has been
posing a therapeutic challenge. Quite a number of
definitive therapeutic options have been tested over the
last 2-3 decades, i.e. external ± interstitial irradiation,
mixed beam treatment with protons or neutrons, particle
beam alone, prostatectomy with or without hormono-
and radiotherapy. Traditional treatment planning is more
or less hampered by the difficulty in differential delivery
of a higher dose to the prostate and sparing surrounding
sensitive normal tissue. Hormonal therapy is combined
with local treatment, with the belief of an additive or
synergistic effect improving local control. Unfavourable
geometrical conditions, target volume inaccuracy, the risk
of set-up systemic and random errors and internal organ
motion occurring during external beam irradiation are
important limitations for dose escalation. Technological
progress and development of three-dimensional treatment
planning systems has permitted an accurate confirmation
of the prescribed dose to the prostate target volume and
to modulate dose intensity (conformal and dose intensity
modulated radiotherapy – CERT, IMRT). These
developments have provided an opportunity to escalate
highly conformal doses, which can be translated into
a significant benefit in “no biochemical evidence of
disease” survival and in “cause-specific” survival [3-5].
The next important step forward was the develo-
pment of a new conformal 3D-real time brachytherapy
system using ultrasound–guided interstitial prostate
implantations and on-line dosimetry (3D-CBRT). Among
the many advantages specified in part I of this paper [1]
two of them seem to be the most important.
First of all, this allows to combine both conformal
techniques of external and interstitial irradiation to
increase dose intensity within the accurately defined
target. The second advantage is the shortening of the
overall treatment time.
Martinez and his group from the W. Beaumont
Center, USA have gained the largest experience in testing
the applicability, tolerance and effectiveness of the 3D-
CBRT as a monotherapy, interdigited or boost treatment
of prostate cancer [2, 4-7].
They have been the first team to suggest the use of
3D-CBRT in two or three fractions, combined interdigi-
tally with external beam irradiation (Table V). Their study
[5] was performed on both favourable and unfavourable
cases. The authors have noted a 30% gain in 5-year
BNED for the group treated with two fractions of either
8.25 Gy, 8.75 Gy, 9.50 Gy, 10.50 Gy or 11.5 Gy given in
day 5 and 19 during the course of external irradiation
(ERT), as compared to a combination of 3 fractions of
5.5Gy,6.0 Gy or 6.5 Gy on day 5, 12, 19 of the ERT (87%
vs. 57% in Table V, A1-A2). Compared with the
Figure 2. Dose measurements scattergrams for (a) D100PTV, (b) D90, and (c) D10
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conventional 7 weeks of external radiotherapy, the overall
treatment time has been shortened by 16 days (i.e. from
49 to 33 days). Both external and 3D-CBRT were well
tolerated by the patients and the incidence of late 5-year
actuarial moderate urinary complications (grade III) was
about 8%; with only 0.5% of gastrointestinal grade III°
complications. An interesting suggestion is to use 3D-
CBRT as monotherapy, consisting of 4 fractions (twice-a-
day) of 9.5 Gy in 2 days [6]. Preliminary results look very
encouraging, with 17% of acute effects and without grade
III-IV acute complications (Table V,C).
To test a new technique of 3D-CBRT we have started
a detailed pilot clinical study using 10 Gy as a single boost
dose (Table V,D). The advantage of our schedule as
compared with the studies of Martinez is that both
external and interstitial irradiation were conformal. We
found this schedule feasible and very well tolerated by
patients. The low incidence of grade III effects in our
series is similar to that reported by Martinez et al [2, 5, 6].
Although it is almost impossible to distinguish between
the acute effects related to external and interstitial
irradiation, the 3D-CBRT did not cause any increase in
the severity of acute effects. Mild perineal pain in 11% of
patients was transient, and did not influence the level of
good tolerance.
Dosimetric results showed that the parameters of
D100PTV, D90 and D10 were within the acceptable limits
recommended by the American Brachytherapy Society
and similar to those reported by Martinez. It may suggest
that 3D-CBRT is a precise conformal technique of
treatment. Prostate motion may influence dose dosimetry
and it is likely to be a serious problem in external beam
radiotherapy. It calls the use of larger PTV. However, for
the single dose of 3D-CBRT used in our study this
problem can be ignored. Martinez et al. [2] have pointed
out that the prostate motion is predominantly in the
superior portion of the gland and in the anterior-posterior
direction and it may occur between fractions with the
potential to change the dose received by the target.
However, the authors did not detect significant
anterioposterior motion. Using real-time TRUS imaging
with on-line dosimetry they have been able to make
corrections for minor prostate displacement and to
contour any changes prior to each conformal CBRT
fraction.
The main objective of conformal 3D-ERT and 3D-
CBRT is to improve locoregional control and long-term
BNED. Although our early results are encouraging, the
interpretation should be very careful. In contrast to
Martinez’s studies, which had included a wide range of
favourable and unfavourable cases, our pilot study
included only T1-2N0M0 prostate cancer patients, mostly
with favourable PSA level and Gleason score. Therefore
the relatively high rate of 97% of 1-year BNED is not
surprising. Gaining experience in the first step of clinical
studies on 3D-CBRT, the combination 3D-CBRT
fractions interdigited with external conformal ERT looks
very promising, especially because the dose can be further
intensified by shortening the overall treatment time by
another 1-1? weeks.
A significant, and probably the most important
advantage, is the radiobiologic benefit of 3D-CBRT.
Brenner and Hall [11] have, in 1999, presented the
suggestion that the sensitivity of prostate cancer to
changes in dose-per-fraction might be extremely and
uniquely high. Despite the criticism raised of by some
authors, there is significant experimental and clinical
evidence that the α/β ratio for prostate cancer could be
very low (1.5 Gy with 95% CI: 0.8-2.2 Gy), and much
lower than that for late responding tissues [8-10). Using
the Martinez data for 3D-CBRT [5] Brenner et al. [11]
estimated an α/β ratio of 1.2 Gy (95% CI: 0.03-4.1 Gy).
Comparing α/β values estimated for various sets of
data of the ERT and/or BRT, D’Souza and Thames [9]
have concluded that the uncertainties might be inherent
in such comparisons (differences in dose distribution,
dose rate, and type of radiation) and they imply that
a broad range of α/β ratios is possible but still with the
value remaining low.
If this is true, and the α/β value for prostate cancer
control is low, the consequences for prostate cancer
radiotherapy could be significant and leading to
hypofractionation as an ideal solution. This radiobiolo-
gical rationale was used by Stromberg and Martinez [7] to
design hypofractionated 3D-CBRT interdigitated with
external irradiation. Four daily fractions of external
irradiation prior to each implant fraction at the end of
week 1, 2 and 3 were assumed to depopulate tumour
cells. Three CBRT fractions should prevent sublethal
damage repair at the cellular level. The biologically
equivalent doses (BED) calculated for two CBRT regimes
(Table V, A-2 and C) are considerably high, in the range
of 119-131 Gy1.5. Such BED would be extremely difficult
to achieve even with external IMRT.
Using different ERT and BRT fraction sizes it is
difficult to compare the biological effectiveness of various
treatment schedules. Therefore, we used the following
Normalized Biologically Effective Dose (NBED) formula
proposed by Fowler et al [10]:
NBED = Dnew (1 + dnew/α/β) / (1 + 2.0/ α/β)
which allows to normalize various schedules to
a conventional 2.0 Gy fraction regimen. Table V shows the
NBED values for three  α/β ratios representing acutely
responding tissue (i.e. the mucosa) (α/β=10 Gy), the
rectum (α/β=3.0 Gy), and prostate cancer (α/β=1.5 Gy).
For schedule “A-2” the NBED for prostate cancer is
131.4 Gy1.5 and for rectum and normal mucosa the
respective NBED are lower by 15% and 20%, respec-
tively. It suggest that the therapeutic gain in the tumour
can be achieved together with a lower risk of late rectal
complications and even with lower risk of acute mucosal
effects which, in fact, has been noted in the Martinez and
their studies. For CBRT as monotherapy (Table V,C) the
difference between biological doses for tumour and
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normal tissues is even larger. In our pilot study this
tendency can also be noted with NBED of 86.8 Gy1.5 for
the prostate (Table V,D). It suggests that there is still
room to escalate the boost dose delivered by 3D-CBRT.
Fowler et al. [10] suggest to use 10 fractions of 4.77 Gy. It
would overdose the prostate tumour by 15.3% BED,
equivalent to a NTD of 85 Gy in 2 Gy fractions, whereas
the rectal tissue would receive the equivalent of a NTD of
74 Gy. This would also cause a 10% reduction in NTD for
early responding tissues. It is difficult to decide which
combination of CERT and CBRT may provide the highest
benefits, but there is no doubt that conformal ERT
combined or interdigitated with a TRUS–guided real
time conformal brachytherapy boost provides precise
dose delivery. This is well tolerated and effective
treatment modality for some patients with prostate cancer
(especially with a large target volume). The accurate
selection of patients and the choice of an optimal
combination of irradiation regimes need further clinical
studies and randomized trials to evaluate the real
beneficial effect.
Conclusions
A pilot study on 3D-real time CBRT using a single boost
dose of 10 Gy combined with 54 Gy in 27 fractions of
conformal external irradiation has provent that this is
a well tolerated treatment modality in case of patients
with T1-2N0M0 prostate cancer. There is still radiobio-
logical room to intensify the treatment towards frac-
tionated 3D-real time CBRT interdigited with external
irradiation.
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